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ABSTRACT
Objective: To determine if amoxicillin/clavulanate potassium is effective in the treatment of Chlamy-
dia trachomatis endocervicitis.
Methods: Thirty-two patients with culture-proven endocervical infection were treated with
amoxicillin/clavulanate potassium, 500 mg orally 3 times a day for 10 days. Post-treatment endocer-
vical specimens were obtained at 2, 4, and 6 weeks for culture ofC. trachomatis. Male partners were
treated with doxycycline, 100 mg orally twice daily for 10 days. The couples were provided condoms
and asked to use them throughout the duration of the study.
Results: All patients treated with amoxicillin/clavulanate potassium were cured of signs of cervi-
citis. All were found to be free of C. trachomatis at their follow-up visits.
Conclusions: Amoxicillin/clavulanate potassium is effective in eradicating C. trachomatis.
(C) 1993 WileyoLiss, Inc.
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hlamydia trachomatis is considered to be the most
common sexually transmitted bacterium in the
United States. It is estimated that 4 million infec-
tions occur per year. In the female, C. trachomatis
is one etiologic agent responsible for cervicitis, ure-
thritis, endometritis, and salpingitis.
2-s C. tra-
chomatis has been associated with abortion, prema-
ture rupture of amniotic membranes, premature
labor, chorioamnionitis, and postpartum endo-
metritis.
6-1 Like other sexually transmitted dis-
eases, C. trachomatis can be found in association
with other bacteria, e.g., Neisseria gonorrhoeae in
60% of cases.
11 Standard treatment has been tetra-
cycline in the non-pregnant patient and doxycycline
or erythromycin in the pregnant patient. Recently,
clindamycin has been shown to be effective and
synergistic when combined with gentamicin.
12 Var-
ious penicillins have been shown to be effective in
vitro and in vivo.
13-16
The present study was undertaken to determine
if the combination of amoxicillin plus clavulanate
potassium (Augmentin, Beecham Laboratories,
Bristol, TN) is effective in eradicating C. trachom-
at#. This agent was chosen for its broad spectrum
of activity. In vitro studies have shown that it is
effective against Gardnerella vaginalis (S. Faro, per-
sonal communication), a significant advantage be-
cause patients with C. trachomatis are commonly
found to be positive for G. vaginalis as well. In
addition, the presence of G. vaginalis may indicate
an abnormal vaginal flora dominated by anaerobic
bacteria, e.g., bacterial vaginosis. Augmentin is
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suitable not only against anaerobes but also against
facultative anaerobes and gram-positive aerobes.
Augmentin has also been shown to be effective
against [3-1actamase-producing N. gonorrhoeae. For
these reasons, it has the potential for being suitable
as a single agent for the treatment of C. trachomatis,
N. gonorrhoeae, and bacterial vaginosis.
SUBJECTS AND METHODS
Study subjects were chosen from the patients seen at
the colposcopy clinic of the Department of Obstet-
rics and Gynecology at Baylor College of Medi-
cine. Patients 18 years of age or older were enrolled
if they had chlamydia-positive endocervical cul-
tures, had not used antibiotics within the previous
30 days, and had given written informed consent.
If otherwise eligible, patients younger than 18 but
older than 13 years of age were enrolled if written
informed consent and parental written consent had
been obtained. Patients who were allergic to or
suspected of being allergic to penicillin or who
admitted to having more than one sexual partner
were excluded from the study.
The male partners of all patients enrolled in the
study were treated with doxycycline, 100 mg orally
twice daily for 10 days. An ample supply of con-
doms was given to each patient for the entire dura-
tion of the study. Patients who failed to use the
condoms during sexual intercourse were dropped
from the study. All female patients enrolled in the
study were treated with Augmentin, 500 mg orally
3 times a day for 10 days. Patients were instructed
not to take any other antibiotics during the study
period. Patients were asked to return at 2, 4, and 6
weeks after completion of therapy for test-of-cure
cultures.
Specimens for the isolation and culture of C.
trachomat# were obtained from the endocervix us-
ing a sterile Dacron swab mounted on a plastic
shaft. The portio of the cervix was first cleansed by
gently wiping away with a large cotton swab any
vaginal discharge that may have been present. The
sterile Dacron swab was placed deep into the endo-
cervical canal and rotated in a clockwise manner for
15 to 30 sec. The swab was then placed into Bartel’s
transport medium (Bartel, Bellevue, WA) and
taken immediately o the laboratory for process-
ing.
17 C. trachomatis was isolated on cyclohexim-
ide-treated McCoy cells (Viromed Laboratories,
Minnetonka, MN). C. trachomatis inclusions were
TABLE I. Results of treating Chlamydia trachomatis
with Augmentin
No. of No. of Culture
patients weeks results
4 0 Not done
5 2 Negative
4 2, 4 Negative
18 2, 4, 6 Negative
identified by staining with monoclonal immunoflu-
orescent antibody (Ortho Diagnostics, Raritan,
NJ). All specimens were passed blindly twice in
McCoy tissue cultures.
RESULTS
Thirty-five patients were enrolled in the study and
32 (91%) completed the study by having at least
one follow-up post-treatment culture. Three pa-
tients were excluded from the study: 1) one patient
became dizzy while taking Augmentin and volun-
tarily discontinued the medication; 2) one was seen
by another physician and given doxycycline; and 3)
one failed to use condoms.
Nineteen patients were black (59%), nine were
Hispanic (29%), and four were Caucasian (12.5%).
The ages ranged from 14 to 66 years old, with a
mean of 24 years. The population may reflect the
fact that the colposcopy clinic serves primarily an
indigent population made up largely of black and
Hispanic patients.
Augmentin was well tolerated, with minimal
adverse effects. Two patients developed nausea and
vomiting. However, when they took the medica-
tion after meals, they had no further problems and
completed a full course of therapy. Two patients
developed vaginal discharge and itching. Examina-
tion at their initial follow-up evaluations revealed
the presence of fungal pseudohyphae, and a diagno-
sis of Candida vaginitis was made. Both patients
were treated successfully with butoconazole.
Thirty-two patients completed a 10-day course
ofAugmentin. Nine patients returned only for their
initial 2-week visit. Five patients returned for their
2- and 4-week visits, and 18 patients returned for
their 2-, 4-, and 6-week visits (Table 1).
Thirty-one patients had negative follow-up cul-
tures of the endocervix. However, one patient
found to be negative at the 2-week visit was positive
at the 4-week visit. She admitted to having had
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unprotected intercourse after the 2-week post-ther-
apy evaluation. She was re-treated with Augmentin
and subsequently found to be negative at the next
post-therapy evaluation.
One 66-year-old patient was particularly inter-
esting. She had been a widow for 11 years and
stated that she had not engaged in sexual activity
since her husband died. She was found to harbor C.
trachomatis in her endocervical canal. This patient’s
culture was strongly positive, that is, there were
numerous inclusion bodies present. Therefore, the
possibility of it being a false-positive culture could
be unlikely. Augmentin was successful in eradicat-
ing C. trachomatis, as she was found to have nega-
tive cultures at 2, 4, and 6 weeks post-therapy.
DISCUSSION
The current recommended therapy for cervical
chlamydial infection in the non-pregnant patient is
doxycycline, 100 mg orally twice daily for 7 to 10
days. A main disadvantage of doxycycline is its
relatively narrow spectrum of antimicrobial activ-
ity. Thus, it is frequently prescribed as an "add-on"
antibiotic for patients in whom pelvic inflamma-
tory disease is suspected or diagnosed.
Chlamydial infection in the pregnant patient is
primarily treated with erythromycin, 500 mg orally
4 times a day for 7 to 10 days. However, erythro-
mycin frequently causes gastrointestinal distur-
bances, which, in pregnancy, represent a common
complication. Therefore, in the pregnant patient
treated with erythromycin, compliance is a signifi-
cant problem.
Azithromycin, a new macrolide, is approved for
the treatment of C. trachomatis in a single daily
dose. However, this agent has not been approved
for use in pregnancy nor in the treatmento gonor-
rhea. Ofloxacin has been shown to be effective and
has been approved for the treatment of both N.
gonorrhoeae and C. trachomatis. However, quinolo-
nes are contraindicated in pregnant patients, breast
feeding patients, and children under the age of 16.
In addition, ofloxacin has a limited spectrum of
activity against anaerobes; therefore, its use in those
patients with concomitant bacterial vaginosis would
be questionable.
Hospitalized patients with acute salpingitis are
currently treated with cefoxitin, ceftizoxime, ce-
fotetan plus doxycycline, or clindamycin plus gen-
tamicin. Ambulatory treatment of pelvic inflam-
matory disease mainly relies on ceftriaxone plus
doxycycline. Ceftriaxone does not provide adequate
coverage against anaerobes, and one must question
the logic of using a single dose of ceftriaxone, al-
though it has a long half-life, to prevent progres-
sive salpingitis. The goal of treating acute salpingi-
tis is to prevent damage to the fallopian tube,
thereby reducing the risk of ectopic pregnancy
and/or infertility. Despite the reported side effect
of diarrhea, which might limit its use,
5 Augmentin
would seem a more logical choice in treating the
ambulatory patient because of its broader spectrum
of activity.
Recently, amoxicillin has been shown to have
moderate in vitro anti-chlamydial activity. Clinical
trials with amoxicillin used in different dosing reg-
imens have demonstrated efficacy in treating
chlamydial infection. 8’16 Other penicillins have
been shown to have anti-chlamydial activity,
namely, mezlocillin, ticarcillin, timentin, and pip-
eracillin.
14--17
Augmentin was chosen for study because it is
active against penicillinase-producing strains ofN.
gonorrhoeae, G. vaginalis, and gram-positive or-
ganisms, e.g., Streptococcus agalactiae, Staphylococ-
cus aureaus, and Enterococcusfaecalis. Augmentin is
active against many members of the Enterobacteri-
ace.ae and anaerobes. The presence of clavulanate
potassium, a [3-1actamase inhibitor, increases the
spectrum of activity of amoxicillin, especially
against [3-1actamase-producing bacteria. Our study
showed that this antibiotic is effective therapy for
C. trachomatis infections.
Augmentin presents the opportunity of using a
single agent for the treatment ofN. gonorrhoeae and
C. trachomatis cervicitis. Augmentin also affords
the opportunity to treat bacterial vaginitis in the
non-pregnant and pregnant patient who is not aller-
gic to penicillin. Additional studies are needed to
confirm its activity in the treatment of bacterial
vaginosis. Its spectrum of activity makes it a poten-
tial agent for the treatment of pelvic inflammatory
disease in an ambulatory setting.
Although the activity of Augmentin is probably
no better than ampicillin or amoxicillin against C.
trachomatis, it does offer advantages, as already
stated, over these other penicillins. However, ampi-
cillin or amoxicillin could be used for the treatment
of C. trachomatis cervicitis in pregnancy. In the
non-pregnant patient, Augmentin would be prefer-
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able to the other oral penicillins because of its
broader spectrum of activity, thus playing a greater
preventive role with regard to fallopian tube dam-
age. In this instance, the additional cost of Aug-
mentin may be justified. However, further investi-
gation of the role of this agent in treating female
pelvic infection is warranted.
Augmentin, in the present study, proved to be
100% effective in eradicating C. trachomatis from
the cervix. One patient was initially treated and
found to be cured, but was subsequently found to
be positive, re-treated, and cured. Thus, Augmen-
tin appears to be a suitable agent for the treatment
of chlamydial cervicitis in the pregnant and non-
pregnant patient.
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